Future oncology最新文献

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma. ECHELON-3研究总结：brentuximab vedotin联合治疗弥漫性大b细胞淋巴瘤

IF 3 4区医学

Future oncology Pub Date : 2025-06-19 DOI: 10.1080/14796694.2025.2513219

Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Juan-Miguel Bergua, Krimo Bouabdallah, Nicholas Forward, Fontanet Bijou, David MacDonald, Craig A Portell, Herve Ghesquieres, Grzegorz Nowakowski, Christopher A Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Fei Jie, Jeong-A Kim

引用次数: 0

Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis. TMZ + RT联合其他药物治疗胶质母细胞瘤的疗效和安全性：一项网络meta分析。

IF 3 4区医学

Future oncology Pub Date : 2025-06-18 DOI: 10.1080/14796694.2025.2516408

Simin Wang, Jiyong Wu, Wenfei Zhang, Jing Nie

{"title":"Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis.","authors":"Simin Wang, Jiyong Wu, Wenfei Zhang, Jing Nie","doi":"10.1080/14796694.2025.2516408","DOIUrl":"https://doi.org/10.1080/14796694.2025.2516408","url":null,"abstract":"Introduction: Temozolomide combined with radiotherapy has been widely recognized as the first-line treatment for glioblastoma. However, a standard treatment regimen for recurrent glioblastoma after treatment with temozolomide plus radiotherapy is lacking at present. This network meta-analysis aimed to assess and rank the therapeutic efficacy and safety of temozolomide plus radiotherapy combined with 11 other anti-cancer treatments in glioblastoma so as to provide valuable evidence for appropriate clinical decision-making.Methods: Eligible studies investigating the efficacy and safety of temozolomide plus radiotherapy (standard treatment) compared to combination therapies were obtained by searching PubMed, Cochrane Library, and EMBASE. Outcomes included progression-free survival, overall survival, and grade 3-5 adverse events.Results: A total of 16 studies were included in this meta-analysis. Except for autologous lymphoid effector cells specific against tumor, galunisertib, and interferon-β, other anti-cancer treatments used in combination with standard treatment resulted in a survival advantage over standard treatment alone. The combination of nimustine with standard treatment performed best in improving overall survival and progression-free survival and exhibited a favorable safety profile, making it the optimal treatment option for recurrent glioblastoma.Conclusion: After a comprehensive safety analysis, nimustine and lomustine were identified as effective drugs that could be combined with standard treatment.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251004329.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET. 多模态成像在癌症检测中的作用：SPIONs和USPIONs作为MRI、SPECT和PET的造影剂。

IF 3 4区医学

Future oncology Pub Date : 2025-06-18 DOI: 10.1080/14796694.2025.2520161

Zahra Shaghaghi, Ramin Mansouri, Sahar Nosrati, Maryam Alvandi

{"title":"Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.","authors":"Zahra Shaghaghi, Ramin Mansouri, Sahar Nosrati, Maryam Alvandi","doi":"10.1080/14796694.2025.2520161","DOIUrl":"https://doi.org/10.1080/14796694.2025.2520161","url":null,"abstract":"Nanomedicine has emerged as a transformative field in medical diagnostics, particularly in cancer detection. Superparamagnetic iron oxide nanoparticles (SPIONs) and ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) have garnered significant attention due to their remarkable properties, making them suitable for use in molecular imaging. These nanoparticles can serve as effective contrast agents for magnetic resonance imaging (MRI) and can also be radiolabeled with various radioisotopes for use in nuclear medicine modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Recent advancements in multimodal imaging systems, such as PET/MRI and SPECT/MRI, have demonstrated the potential of these nanoparticles to combine the strengths of different imaging techniques, allowing for more accurate cancer detection at early stages. MRI provides high spatial and temporal resolution but lacks sensitivity, while PET and SPECT offer high sensitivity with lower resolution. The integration of these modalities allows for enhanced imaging of cancerous tissues. This review discusses the application of radiolabeled SPIONs and USPIONs in dual-modality imaging systems, highlighting their advantages and limitations as contrast agents. The continued development of targeted nanoprobes and the exploration of new multimodal imaging systems offer promising avenues for improving early cancer diagnosis and treatment.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of the imCORE Network during and post the COVID-19 pandemic: shifting priorities in oncology clinical trials. COVID-19大流行期间和之后imCORE网络的演变：肿瘤学临床试验重点的转移

IF 3 4区医学

Future oncology Pub Date : 2025-06-17 DOI: 10.1080/14796694.2025.2520147

Sarah Helou, Tanya Vidhyarkorn, San Tran, Catherine Scher, Sarah Churchill, Janice Russell

{"title":"Evolution of the imCORE Network during and post the COVID-19 pandemic: shifting priorities in oncology clinical trials.","authors":"Sarah Helou, Tanya Vidhyarkorn, San Tran, Catherine Scher, Sarah Churchill, Janice Russell","doi":"10.1080/14796694.2025.2520147","DOIUrl":"https://doi.org/10.1080/14796694.2025.2520147","url":null,"abstract":"Background: The immunotherapy Centers of Research Excellence (imCORE) Network is a worldwide research network. Pre-coronavirus disease 19 (COVID-19) pandemic, the Network established itself as a partnership model leader with several years of experience. COVID-19 directly impacted clinical research conduct, imCORE sites, patients, and how the network operates.Methods: The sponsor created a survey assessing operational priorities of Network sites pre-COVID-19, immediately post-COVID-19, and present day. The survey asked each site to prioritize 14 operational aspects of clinical research at the three separate timepoints allowing for data comparison between the timepoints.Results: This paper highlights the impacts of COVID-19 to the operational priorities of imCORE sites. This includes specific measures taken to evolve to fit the needs of its sites and their patients, and presents a path forward for site networks to consider in the new reality of COVID-19 era clinical trials.Conclusions: Site networks positively impacted site knowledge and experience through the pandemic and beyond. Sponsors must recognize each site as a unique entity with their own priorities and focus while understanding a commonality of priorities within regions and among research sites globally. We recommend the creation of site networks to further strengthen the sponsor-site relationship.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment. 早期乳腺癌患者对治疗途径的偏好：离散选择实验的应用。

IF 3 4区医学

Future oncology Pub Date : 2025-06-16 DOI: 10.1080/14796694.2025.2517000

Christian Jackisch, Chikako Shimizu, Emuella Flood, Oliver Will, Susan McCutcheon, Stella Mokiou, Xavier Guillaume, Emily Mulvihill, Kathleen Beusterien

{"title":"Patient preferences for treatment pathways in early-stage breast cancer: application of a discrete choice experiment.","authors":"Christian Jackisch, Chikako Shimizu, Emuella Flood, Oliver Will, Susan McCutcheon, Stella Mokiou, Xavier Guillaume, Emily Mulvihill, Kathleen Beusterien","doi":"10.1080/14796694.2025.2517000","DOIUrl":"https://doi.org/10.1080/14796694.2025.2517000","url":null,"abstract":"Aim: This study assessed patient preferences for four clinical trial pathways, which include multiple sequential treatments, in human epidermal growth factor receptor 2-negative early-stage breast cancer (eBC). It presents an innovative application for a discrete choice experiment (DCE), yielding single-preference weights for complex pathways.Materials & methods: Patients in Germany, Italy, and Japan with stage II/III BC completed an online DCE, which included a series of choice tasks with two hypothetical treatment profiles that varied in attributes associated with four eBC treatment pathways: overall pathway (event-free survival, fixed versus flexible, duration) and treatment-specific (side effects, regimen). Bayes modeling was used to estimate preference weights for each attribute level. Preferences for different eBC pathways were calculated by summing the respective pathway and treatment weights, adjusted for the duration of the respective treatments along the pathway. Mean pathway preference weights were compared among the four pathways and countries using analyses of variance.Results: Pathway preferences were highly sensitive to treatment toxicity and surgical response. Additionally, a flexible pathway was preferred as it can mean a shorter pathway duration.Conclusion: Discussions with patients should be personalized per individual preferences and should cover the entire treatment pathway, not just the initial treatment step.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study. 新辅助治疗后乳腺癌复发的预测危险因素：NEORISK研究

IF 3 4区医学

Future oncology Pub Date : 2025-06-14 DOI: 10.1080/14796694.2025.2516410

Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi, Fabio Marazzi, Antonino Mule, Paolo Belli, Alessandro Rossi, Stefano Magno, Antonella Palazzo, Valeria Masiello, Angela Santoro, Paola Fuso, Emilio Bria, Sabatino D'Archi, Lorenzo Scardina, Alejandro Martin Sanchez, Diana Giannarelli, Stefano Paternello, Giorgia Garganese, Giovanni Scambia, Giampaolo Tortora, Riccardo Masetti, Gianluca Franceschini, Alessandra Fabi

{"title":"Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.","authors":"Franco Antonio, Luisa Carbognin, Ida Paris, Alba Di Leone, Armando Orlandi, Fabio Marazzi, Antonino Mule, Paolo Belli, Alessandro Rossi, Stefano Magno, Antonella Palazzo, Valeria Masiello, Angela Santoro, Paola Fuso, Emilio Bria, Sabatino D'Archi, Lorenzo Scardina, Alejandro Martin Sanchez, Diana Giannarelli, Stefano Paternello, Giorgia Garganese, Giovanni Scambia, Giampaolo Tortora, Riccardo Masetti, Gianluca Franceschini, Alessandra Fabi","doi":"10.1080/14796694.2025.2516410","DOIUrl":"https://doi.org/10.1080/14796694.2025.2516410","url":null,"abstract":"Background: Neoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.Methods: A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.Results: Lower 5-year EFS was linked to axillary staging (cN, p < 0.001), molecular subtype (p < 0.001), surgery type (p = 0.030), and post-surgical nodal status (ypN, p = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.Conclusion: Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer. 外泌体：结直肠癌诊断、预后和治疗的潜在工具。

IF 3 4区医学

Future oncology Pub Date : 2025-06-14 DOI: 10.1080/14796694.2025.2520150

Azmin Akter, Tasnima Kamal, Sharmin Akter, Abdul Auwal, Farhadul Islam

{"title":"Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer.","authors":"Azmin Akter, Tasnima Kamal, Sharmin Akter, Abdul Auwal, Farhadul Islam","doi":"10.1080/14796694.2025.2520150","DOIUrl":"https://doi.org/10.1080/14796694.2025.2520150","url":null,"abstract":"Colorectal cancer (CRC), a commonly diagnosed malignancy, is one of the most frequent causes of cancer-related deaths worldwide. To effectively lower the death rate from this disease, it is essential to create public health methods, including developing new biomarkers that facilitate screening, diagnosis, prognosis, and therapy response prediction. CRC-derived Exosomes are a type of extracellular vesicle that transport functional molecules like proteins, lipids, nucleic acids (DNA, mRNA, miRNA, lncRNA, and noncoding RNA), and other metabolites, which act as molecular cargos to facilitate transportation. Exosomes generated and secreted from cancer cells are key biomarkers for early, noninvasive cancer diagnosis, prognosis, and treatment response, with their biogenesis in CRC offering molecular insights. Their expression varies across time, tissues, and disease stages. Thus, the development of innovative and effective techniques for isolating and detecting exosomes holds great potential for tumor diagnosis, prognosis prediction, and developing techniques (MSC-derived exosome, DC-derived exosome, engineered exosome, etc.) and their contents to improve the specificity and efficacy of therapies for patients with CRC. This review explores the features and formation of CRC-derived exosomes, highlighting their diagnostic, prognostic, and therapeutic significance through a comprehensive analysis of exosome extraction, identification, purification, and documented biological roles in existing literature.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-19"},"PeriodicalIF":3.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. 复发或转移性HNSCC中petosemtamab + pembrolizumab和petosemtamab单药治疗的LiGeR-HN III期试验。

IF 3 4区医学

Future oncology Pub Date : 2025-06-13 DOI: 10.1080/14796694.2025.2511470

Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad, Douglas Adkins, Maura Gillison, Kevin J Harrington, Sung-Bae Kim, Christophe Le Tourneau, Amanda Psyrri, Ari Rosenberg, Lillian L Siu, Makoto Tahara, William N William, Jim Ford, Shekeab Jauhari, Rebecca Pyle, Yu-Ming Shen, David Yao, Fabian Zohren, Everett Vokes

{"title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.","authors":"Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad, Douglas Adkins, Maura Gillison, Kevin J Harrington, Sung-Bae Kim, Christophe Le Tourneau, Amanda Psyrri, Ari Rosenberg, Lillian L Siu, Makoto Tahara, William N William, Jim Ford, Shekeab Jauhari, Rebecca Pyle, Yu-Ming Shen, David Yao, Fabian Zohren, Everett Vokes","doi":"10.1080/14796694.2025.2511470","DOIUrl":"https://doi.org/10.1080/14796694.2025.2511470","url":null,"abstract":"Patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) have limited treatment options and a dismal prognosis, especially when their cancer is resistant to standard treatments like anti-programmed cell death protein 1 and platinum-based therapies. Petosemtamab - a human, common light chain, bispecific antibody with enhanced antibody-dependent cellular cytotoxicity targeting epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) - demonstrated antitumor activity in r/m HNSCC. In many tumor types, including HNSCC, EGFR is an oncogenic driver, while LGR5 is upregulated. LGR5 can potentiate the wingless-type integration site (WNT)/β-catenin signaling pathway in response to ligand binding, stimulating cancer stem cell proliferation and self-renewal. This article describes two registration-intent, open-label, randomized phase III trials evaluating efficacy and safety of petosemtamab. LiGeR-HN1 (NCT06525220) evaluates petosemtamab plus pembrolizumab versus pembrolizumab as first-line therapy for patients with programmed cell death ligand 1-positive r/m HNSCC. LiGeR-HN2 (NCT06496178) evaluates petosemtamab versus investigator's choice of monotherapy (cetuximab, methotrexate, or docetaxel) in patients with previously treated r/m HNSCC. Primary endpoints in both trials are objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review, and overall survival. Both trials are recruiting at the time of publication.Clinical Trial Registration: NCT06525220 and NCT06496178 (ClinicalTrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma. II期PANDORA试验的设计和基本原理：晚期默克尔细胞癌的一线化学免疫治疗。

IF 3 4区医学

Future oncology Pub Date : 2025-06-12 DOI: 10.1080/14796694.2025.2514402

Simone Oldani, Natalie Prinzi, Federica Morano, Sara Cingarlini, Anna Maria Di Giacomo, Monica Niger, Michele Prisciandaro, Alessandra Raimondi, Giovanni Randon, Chiara Carlotta Pircher, Michele Borghesani, Monica Valente, Elvira Rostanzo, Massimo Milione, Giovanna Sabella, Tommaso Cascella, Filippo Ghelardi, Carolina Sciortino, Eleonora Gusmaroli, Vincenzo Nasca, Filippo de Braud, Filippo Pietrantonio, Sara Pusceddu

{"title":"Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma.","authors":"Simone Oldani, Natalie Prinzi, Federica Morano, Sara Cingarlini, Anna Maria Di Giacomo, Monica Niger, Michele Prisciandaro, Alessandra Raimondi, Giovanni Randon, Chiara Carlotta Pircher, Michele Borghesani, Monica Valente, Elvira Rostanzo, Massimo Milione, Giovanna Sabella, Tommaso Cascella, Filippo Ghelardi, Carolina Sciortino, Eleonora Gusmaroli, Vincenzo Nasca, Filippo de Braud, Filippo Pietrantonio, Sara Pusceddu","doi":"10.1080/14796694.2025.2514402","DOIUrl":"https://doi.org/10.1080/14796694.2025.2514402","url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin with an aggressive behavior and high propensity for locoregional recurrence and metastasis. The therapeutic options in the metastatic disease are limited and are mainly based on immunotherapy or platinum-based doublets. Importantly, a significant proportion of patients experience resistance to single-agent immunotherapy highlighting the need for more active upfront combinations. The PANDORA trial [NCT06086288] is an open label, multicenter, phase II trial evaluating the activity and safety of pembrolizumab combined with cisplatin or carboplatin and etoposide as first line treatment in patients with advanced MCC. The primary endpoint is objective response rate (ORR). Secondary objectives include overall survival (OS), progression free survival (PFS) and duration of response (DOR). Exploratory objectives include identification of immune and molecular biomarkers and assessment of Health-Related Quality of Life of pembrolizumab plus cisplatin/carboplatin and etoposide in participants with advanced/metastatic MCC. We planned to enroll 35 patients according to the study design. The combination of immune checkpoint inhibitors and chemotherapy was associated with better outcomes compared to either treatment alone in several cancer thanks to a potential synergy. Moving from a biological and clinical rationale, PANDORA may impact on the therapeutic landscape of MCC.Clinical Trial Registration: NCT06086288 (ClinicalTrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Mirvetuximab soravtansine用于上皮性卵巢癌、输卵管癌或原发性腹膜癌的治疗。

IF 3 4区医学

Future oncology Pub Date : 2025-06-12 DOI: 10.1080/14796694.2025.2513848

Jordyn Silverstein, Alexandra Smick, Bridget Johnson, Gottfried E Konecny

引用次数: 0